The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

Opportunities in the Next Generation Cancer Diagnostics Market include leveraging advancements in genomic and proteomic ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

A structural aberration (SA) with secondary implications (SASIs) involving a cancer susceptibility gene is identified on chromosome microarray in approximately 0.6% tests performed on index cases.

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

Study of 99 pediatric patients found clinically significant CNVs in 30% of cases, supporting CMA as a first-tier test for developmental delay and ID. Clinically significant CNVs were identified in 30% ...

Objective: Translation of fertility risks through whole-exome sequencing of family lines to identify variants that explain patient’s clinical phenotypes. Methods: 1. Using techniques such as amniotic ...

Introduction: The genetic basis of congenital heart disease (CHD) is incompletely understood. Approximately 10-20% of infants with CHD have abnormal chromosome microarray (CMA) results, however, the ...

The proportion of children receiving genetic testing was highest for children with both autism spectrum disorder and intellectual disability. Tashalee R. Brown, M.D., Ph.D., from the University of ...

The proportion of children receiving genetic testing was highest for children with both autism spectrum disorder and intellectual disability. HealthDay News — Clinical implementation of genetic ...